Alimera Sciences, Inc. (ALIM)

Market Cap	289.18M
Revenue (ttm)	90.22M
Net Income (ttm)	-22.66M
Shares Out	52.39M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,049
Open	5.52
Previous Close	5.52
Day's Range	5.52 - 5.53
52-Week Range	2.60 - 5.65
Beta	1.15
Analysts	Hold
Price Target	6.00 (+8.7%)
Earnings Date	Aug 8, 2024

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 154
• Stock Exchange: NASDAQ
• Ticker Symbol: ALIM

Financial Performance

In 2023, ALIM's revenue was $80.75 million, an increase of 49.19% compared to the previous year's $54.13 million. Losses were -$21.39 million, 18.1% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for ALIM stock is "Hold." The 12-month stock price forecast is $6.0, which is an increase of 8.70% from the latest price.

Price Target

$6.0

(8.70% upside)

Analyst Consensus: Hold